Rus Iosif Vladut

Dr. Rus Iosif Vladut


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CFCatalin Vladut Ionut Feier
Catalin Vladut Ionut Feier
VGVasile Gaborean
Vasile Gaborean
IFIonut Flaviu Faur
Ionut Flaviu Faur
RVRazvan Constantin Vonica
Razvan Constantin Vonica
AFAlaviana-Monique Faur
Alaviana-Monique Faur
Muntean CalinMuntean Calin
Muntean Calin
Background and Objectives: Postoperative pancreatic fistula and post-hepatectomy liver failure remain significant complications after HPB surgery; however, superficial surgical site infection (SSI) is the most frequent wound-related complication. Closed-incision negative-pressure wound therapy (ciNPWT) has been proposed to reduce superficial contamination, yet no liver-focused quantitative synthesis exists. We aimed to evaluate the effectiveness and safety of prophylactic ciNPWT after hepatopancreatobiliary (HPB) surgery. Methods: MEDLINE, Embase, and PubMed were searched from inception to 30 April 2025. Randomized and comparative observational studies that compared ciNPWT with conventional dressings after elective liver transplantation, hepatectomy, pancreatoduodenectomy, and liver resections were eligible. Two reviewers independently screened, extracted data, and assessed risk of bias (RoB-2/ROBINS-I). A random-effects Mantel–Haenszel model generated pooled risk ratios (RRs) for superficial SSI; secondary outcomes were reported descriptively. Results: Twelve studies (seven RCTs, five cohorts) encompassing 15,212 patients (3561 ciNPWT; 11,651 control) met the inclusion criteria. Device application lasted three to seven days in all trials. The pooled analysis demonstrated a 29% relative reduction in superficial SSI with ciNPWT (RR 0.71, 95% CI 0.63–0.79; p < 0.001) with negligible heterogeneity (I2 0%). Absolute risk reduction ranged from 0% to 13%, correlating positively with the baseline control-group SSI rate. Deep/organ-space SSI (RR 0.93, 95% CI 0.79–1.09) and 90-day mortality (RR 0.94, 95% CI 0.69–1.28) were unaffected. Seven studies documented a 1- to 3-day shorter median length of stay; only two reached statistical significance. Device-related adverse events were rare (one seroma, no skin necrosis). Conclusions: Prophylactic ciNPWT safely reduces superficial SSI after high-risk HPB surgery, with the greatest absolute benefit when baseline SSI risk exceeds ≈10%. Its influence on deep infection and mortality is negligible.

19 September 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
CFCatalin Vladut Ionut Feier
Catalin Vladut Ionut Feier
Florin GramaFlorin Grama
Florin Grama
GMGeorgiana Viorica Moise
Georgiana Viorica Moise
RVRazvan Constantin Vonica
Razvan Constantin Vonica
VGVasile Gaborean
Vasile Gaborean
Muntean CalinMuntean Calin
Muntean Calin
Background: Systemic inflammatory indices are increasingly used to predict prognosis in colorectal cancer (CRC), yet direct comparisons between colon cancer (CC) and rectal cancer (RC) remain limited. Methods: We conducted a retrospective matched-cohort study including 296 patients (148 with CC and 148 with RC) surgically treated between January 2018 and December 2024. Patients were matched by tumor stage, sex, and age (±3 years). Preoperative blood samples were used to calculate several inflammatory markers, including Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Monocyte-to-Lymphocyte Ratio (MLR), Systemic Inflammation Response Index (SIRI), Systemic Immune-Inflammation Index (SII), and Aggregate Index of Systemic Inflammation (AISI). Subgroup analyses were performed based on the Charlson Comorbidity Index (>3 vs. ≤3), surgical context (elective vs. emergency), and tumor stage (T1–T2 vs. T3–T4). Results: Colon cancer patients exhibited significantly higher levels of systemic inflammation compared to those with rectal cancer, with notable differences in NLR (3.99 vs. 2.84, p < 0.001), PLR (219.8 vs. 163.3, p < 0.001), SIRI (3.7 vs. 1.91, p = 0.004), SII (1533.8 vs. 847.8, p < 0.001), and AISI (1714.7 vs. 593.6, p = 0.009). These differences remained statistically significant in key subgroups. In elective surgeries, CC patients had elevated PLR (p < 0.001), SIRI (p = 0.003), SII (p < 0.001), and AISI (p = 0.013). Among patients with advanced tumors (T3–T4), CC was associated with higher SII (p < 0.001), AISI (p = 0.008), PLR (p < 0.001), and SIRI (p = 0.004). For those with a Charlson index > 3, CC patients showed significantly higher PLR (p < 0.001), NLR (p < 0.001) and SIRI (p = 0.001). Conclusions: colon cancer presents with a markedly stronger systemic inflammatory response than rectal cancer, particularly in patients with advanced disease, elective surgical treatment, and higher comorbidity burden. These findings suggest that indices such as SIRI, SII, and PLR may serve as valuable stratification tools beyond tumor location in CRC.

1 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CFCatalin Vladut Ionut Feier
Catalin Vladut Ionut Feier
MAMelania Veronica Ardelean
Melania Veronica Ardelean
VGVasile Gaborean
Vasile Gaborean
Muntean CalinMuntean Calin
Muntean Calin
AFAlaviana Monique Faur
Alaviana Monique Faur
MMMarius-Sorin Murariu
Marius-Sorin Murariu
Background/Objectives: Acute calculous cholecystitis remains one of the most frequent surgical emergencies, ranging from mild inflammation to gangrenous forms associated with necrosis and sepsis. Early differentiation between these stages is essential for timely surgical management. This study aimed to evaluate the diagnostic and prognostic value of hematological inflammatory indices—the Aggregate Index of Systemic Inflammation (AISI), the Systemic Immune-Inflammation Index (SII), and the Systemic Inflammation Response Index (SIRI)—in predicting the gangrenous evolution of acute calculous cholecystitis. Methods: A retrospective study was conducted on 435 patients who underwent cholecystectomy between 2016 and 2024 at a tertiary care center. Patients were divided into gangrenous (n = 145) and chronic (n = 290) cholecystitis groups. Preoperative hematological parameters were used to calculate AISI, SII, and SIRI. After histopathological confirmation, patients with GC (gangrenous calculous cholecystitis) were identified, and for each case, two age- and sex-matched controls with chronic CC (calculous cholecystitis) were selected, maintaining a GC:CC ratio of 1:2. Preoperative hematological parameters were used to calculate AISI, SII, and SIRI. Results: All three indices were significantly higher in the gangrenous group (p < 0.001). Logistic regression identified SIRI as the strongest independent predictor of gangrenous cholecystitis (OR = 1.976, p < 0.001). ROC analysis demonstrated excellent discriminative capacity for all markers (AUC > 0.8), with SII achieving the highest diagnostic accuracy (AUC = 0.889, sensitivity 79.5%, specificity 86.3%). Conclusions: AISI, SII, and SIRI represent reliable, easily obtainable, and noninvasive biomarkers for assessing inflammatory severity and predicting gangrenous transformation in acute calculous cholecystitis. Their integration into preoperative evaluation could improve early risk stratification, surgical planning, and patient outcomes.

Verified
Journal Article
Open access
PDF file
Muntean CalinMuntean Calin
Muntean Calin
VGVasile Gaborean
Vasile Gaborean
RVRazvan Constantin Vonica
Razvan Constantin Vonica
AFAlaviana-Monique Faur
Alaviana-Monique Faur
RVRus Iosif Vladut
Rus Iosif Vladut
CFCatalin Vladut Ionut Feier
Catalin Vladut Ionut Feier
Lynch syndrome (LS)—also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC)—is caused by pathogenic germline mutations in DNA mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, and PMS2. Although it accounts for only 1–5% of all colorectal cancers (CRCs), LS presents with a particularly high lifetime cancer risk and often occurs at younger ages. Identifying LS in patients under 60 years old is crucial for targeted surveillance and early interventions. Variations in clinical presentation and prognosis may exist based on the specific gene mutated, yet these patterns are not fully elucidated. This review aims to synthesize data on clinical outcomes among LS patients under 60, with an emphasis on how different MMR gene mutation patterns might influence prognosis, survival, and treatment decisions. Five population-based studies examining CRC patients younger than 60 years were included according to predefined eligibility criteria. Two independent reviewers screened and extracted data focusing on MMR deficiency detection methods (microsatellite instability [MSI] and/or immunohistochemistry [IHC]), rates of confirmed germline mutations, frequency of BRAF testing, and clinical endpoints such as stage distribution, survival outcomes, and recurrence. Risk of bias was assessed using standardized tools appropriate to each study design. The synthesis focused on comparing outcomes among individuals with MLH1, MSH2, MSH6, and PMS2 mutations, as well as delineating the proportion of patients with sporadic MSI under 60 years of age. Across the five studies, MSI positivity in CRC patients under 60 years ranged from 7.5% to 13%. The frequency of confirmed germline MMR mutations varied between 0.8% and 5.2% in specific cohorts, aligning with LS prevalence estimates of 1–5%. Different mutation patterns correlated with some variation in clinical presentation. Cases with MSH2 and MLH1 mutations more frequently exhibited synchronous or metachronous tumors, while MSH6 and PMS2 mutations displayed more heterogeneous IHC patterns. Where survival data were provided, LS patients under 60 years had better overall survival compared to MMR-proficient individuals, though some studies also noted a potential lack of benefit from standard 5-fluorouracil adjuvant therapy in MMR-deficient tumors. Screening by MSI or by IHC—supplemented with BRAF mutation testing to exclude sporadic MSI—facilitates early detection of LS in CRC patients under 60 and highlights notable differences between mutation types. Although overall outcomes for LS patients can be favorable, especially for stage II disease, the precise impact of each specific mutated gene on clinical course remains heterogeneous. Future large-scale prospective studies are needed to clarify optimal screening protocols and individualized treatment strategies for LS patients under 60.

24 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
VGVasile Gaborean
Vasile Gaborean
CFCatalin Vladut Ionut Feier
Catalin Vladut Ionut Feier
RVRazvan Constantin Vonica
Razvan Constantin Vonica
AFAlaviana-Monique Faur
Alaviana-Monique Faur
RVRus Iosif Vladut
Rus Iosif Vladut
Muntean CalinMuntean Calin
Muntean Calin
Background and Objectives: Systemic conversion of stage III–IV non-small-cell lung cancer (NSCLC) to a surgically resectable state with immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibitors (TKIs) creates an emerging cohort of candidates for “salvage” pulmonary resection. No comprehensive evidence synthesis has yet evaluated the feasibility, safety, or oncologic value of this strategy. We aimed to systematically review peri-operative and survival outcomes of salvage lung resection following ICI or TKI therapy. Methods: MEDLINE, Embase, and PubMed were searched (inception–1 May 2025). Studies reporting ≥5 adult NSCLC patients who underwent anatomical lung resection after at least one cycle of ICI or TKI were eligible. Two reviewers screened records, extracted predefined variables, and assessed risk of bias with the Newcastle–Ottawa Scale. Pooled proportions were calculated with a random-effects model. Results: Fourteen observational series (n = 312 patients) met inclusion. Median age was 62 years (range 38–81); 58% were male. Lobectomy (63%) and segmentectomy (21%) were most frequent. Video-assisted/robotic approaches were achieved in 48%. The pooled R0 rate was 93% (95% CI 89–97%); pathologic complete response occurred in 27% (95% CI 19–36%). Major complications (Clavien–Dindo ≥ III) were 11% (95% CI 7–16%), and 30-day mortality was 1.3% (95% CI 0–3%). One-year disease-free and overall survival were 68% and 88%, respectively. Conclusions: Current evidence—albeit heterogeneous—indicates that salvage pulmonary resection after modern systemic conversion therapy is technically feasible, associated with acceptably low morbidity, and yields encouraging short-term oncologic outcomes. Prospective, registry-based studies are needed to define selection criteria and long-term benefit.

13 July 2025 in Diseases
Verified
Journal Article
Open access
PDF file
GMGeorgiana Viorica Moise
Georgiana Viorica Moise
CFCatalin Vladut Ionut Feier
Catalin Vladut Ionut Feier
VGVasile Gaborean
Vasile Gaborean
AFAlaviana-Monique Faur
Alaviana-Monique Faur
RVRus Iosif Vladut
Rus Iosif Vladut
Muntean CalinMuntean Calin
Muntean Calin
Background: Systemic inflammatory markers have emerged as accessible and reproducible tools for oncologic risk stratification, yet their prognostic value in rectal cancer remains incompletely defined, particularly in acute surgical settings. This study aimed to assess six inflammation-based indices—NLR, PLR, MLR, SII, SIRI, and AISI—in relation to tumor stage, recurrence, and outcomes among patients undergoing emergency versus elective resection for rectal cancer. Methods: We retrospectively evaluated 174 patients treated between 2018 and 2024. Pre-treatment blood counts were used to calculate inflammatory indices. Clinical and pathological parameters were correlated with biomarker levels using univariate and multivariate analyses. Results: Pre-treatment inflammation markers were significantly elevated in patients requiring emergency surgery (e.g., NLR: 3.34 vs. 2.4, p = 0.001; PLR: 204.1 vs. 137.8, p < 0.001; SII: 1008 vs. 693, p = 0.007), reflecting advanced tumor biology and immune activation. Notably, these patients also had higher rates of stage IV disease (p = 0.029) and permanent stoma (p = 0.002). Post-treatment, recurrence was paradoxically associated with significantly lower levels of SII (p = 0.021), AISI (p = 0.036), and PLR (p = 0.003), suggesting a potential role for immune exhaustion rather than hyperinflammation in early relapse. Conclusions: Inflammatory indices provide valuable insights into both tumor local invasion and host immune status in rectal cancer. Their integration into perioperative assessment could improve prognostication, particularly in emergency presentations. Post-treatment suppression of these markers may identify patients at high risk for recurrence despite initial curative intent.